Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
Overview
- Phase
- Phase 3
- Intervention
- Radiotherapy
- Conditions
- Prostate Cancer
- Sponsor
- University Medical Center Groningen
- Enrollment
- 280
- Locations
- 12
- Primary Endpoint
- Metastases progression-free survival (MPFS)
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
The overall aim of this project is to test the hypothesis that the addition of ADT to metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Radiotherapy without hormonal therapy
Metastase-directed radiotherapy without the addition of hormonal therapy
Intervention: Radiotherapy
Radiotherapy combined with hormonal therapy
Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)
Intervention: Radiotherapy
Radiotherapy combined with hormonal therapy
Metastase-directed radiotherapy with the addition of of short-term hormonal therapy (6 months)
Intervention: Leuprorelin
Outcomes
Primary Outcomes
Metastases progression-free survival (MPFS)
Time Frame: 2.5 years after treatment
The primary aim of this project is to test the hypothesis that the addition of ADT to MDRT in well-selected PCa patients with oligo-metastatic disease (OM) prolongs the metastases progression-free survival (MPFS) compared to MDRT alone